Efineptakin alfa

Summary

Efineptakin alfa (also called NT‑I7, GX‑I7, or rhIL‑7‑hyFc) is an investigational long‑acting recombinant human interleukin‑7 fused to an Fc fragment. It is being studied as an immune‑modulating agent to correct T‑cell deficiency and boost antitumor immunity in cancers such as Kaposi sarcoma, solid tumours, and high‑grade gliomas.

Mechanism of Action

The molecule mimics native IL‑7, binding the IL‑7 receptor (IL‑7Rα/γc) on naïve and memory T cells. This engagement triggers JAK/STAT signalling that drives lymphocyte survival, proliferation, and differentiation, expanding CD4+, CD8+ and NK cell pools. The Fc fusion prolongs systemic exposure, allowing sustained lymphocyte reconstitution.

What the Research Shows

Early‑phase clinical studies show efineptakin alfa is generally well tolerated and biologically active. A phase I trial in Kaposi sarcoma (8 patients) reported a 42.9% objective response rate and increased CD4+/CD8+ counts, with only mild injection‑site reactions and transient ALT rises. Population PK/PD modeling in a solid‑tumour phase Ib (35 patients) identified a dose‑dependent rise in absolute lymphocyte count and suggested 0.6‑1.2 mg/kg every 6‑12 weeks for further study. In newly diagnosed high‑grade glioma, the maximum tolerated dose was 720 µg/kg; treatment raised lymphocyte counts for >12 weeks, expanded CD8+ clonotypes, and yielded encouraging outcomes in a subset with unmethylated MGMT promoters. A solid‑tumour phase 1b study demonstrated dose‑related increases in circulating CD8+/CD4+ T cells and tumor‑infiltrating lymphocytes. Pre‑clinical murine lung‑cancer work showed improved survival and induction of tertiary lymphoid structures, hinting at synergy with checkpoint blockade.

Reported Benefits

Across studies, efineptakin alfa consistently increased peripheral lymphocyte numbers, including CD4+, CD8+ and NK cells, and enhanced tumor‑infiltrating lymphocytes. Clinical activity has been observed in Kaposi sarcoma and high‑grade glioma, with some patients achieving tumor responses or disease stabilization. Pre‑clinical data suggest it may promote tertiary lymphoid structures, potentially augmenting other immunotherapies.

Limitations of the Evidence

Evidence is limited to early‑phase, non‑randomized trials with small sample sizes, restricting definitive conclusions about efficacy. Responses have been noted mainly in specific subgroups (e.g., HIV‑positive Kaposi sarcoma, MGMT‑unmethylated glioblastoma). Long‑term safety, optimal dosing, and benefit when combined with standard therapies remain unestablished.

Safety Considerations

Reported adverse events are generally mild (grade < 2) and include injection‑site reactions and transient elevations in alanine aminotransferase. No severe cytokine‑release syndrome or autoimmune toxicity has been observed to date, but liver enzymes and injection sites should be monitored during treatment.

How It Is Administered

Efineptakin alfa is delivered by intramuscular or subcutaneous injection. Clinical studies have used doses ranging from 0.06 mg/kg to 1.7 mg/kg, administered every 3 to 12 weeks, with the current recommended phase‑2 range of 0.6‑1.2 mg/kg at 6‑12 week intervals. The formulation is a recombinant Fc‑fused IL‑7 protein.

Routes of Administration

Goals & Uses

• HIV-associated immune deficiencyInfectious Disease / ImmunologyLow
• Sepsis-induced immunosuppressionCritical Care / ImmunologyLow
• Glioblastoma multiforme (GBM)OncologyLow
• Cancer immunotherapy augmentationOncologyModerate
• Immune reconstitution in lymphopeniaImmunologyModerate
• COVID-19 lymphopenia treatmentInfectious DiseaseModerate

Contraindications

• Known hypersensitivity to efineptakin alfa or componentsAllergy/HypersensitivityHigh
• Organ transplant recipients on immunosuppressionTransplantHigh
• Lymphoma or other T-cell malignanciesOncologyHigh
• Active autoimmune diseaseAutoimmunityHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Skin rash / urticariaDermatologicalUncommon
• Flu-like symptoms / systemic reactionsSystemicCommon
• Transient eosinophiliaHematologicalCommon
• SplenomegalyHematologicUncommon
• LymphadenopathyLymphoreticularUncommon

Drug Interactions

• Systemic corticosteroidsModerate
• Cytotoxic chemotherapyModerate
• Immunosuppressive agents (e.g., tacrolimus, cyclosporine)High
• Anti-PD-1/PD-L1 checkpoint inhibitors (e.g., pembrolizumab, nivolumab)Low

Population Constraints

• Severe hepatic or renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Patients with active malignant T-cell disordersOncologicalAbsolute

Regulatory Status

• European UnionInvestigationalUnder clinical investigation; no EMA marketing authorization.
• United StatesInvestigationalFDA Fast Track designation for multiple oncology indications including GBM. Multiple active IND-supported Phase I/II trials.
• United KingdomInvestigationalNo MHRA approval; investigational use only.

Granted Fast Track designation by the US FDA for multiple oncology indications. Not yet approved in any jurisdiction; multiple Phase I/II clinical trials ongoing globally.

Evidence & Sources

• Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
  Journal ArticleModerateRamaswami R, et al.2025-01-01T00:00:00.000000Z
• Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer
  Journal ArticleModeratePark S, et al.2025-01-01T00:00:00.000000Z
• NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas
  Journal ArticleModerateButt OH, et al.2026-01-01T00:00:00.000000Z
• The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review
  Journal ArticleModerateHesari M, et al.2023-01-01T00:00:00.000000Z
• GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8(+)/CD4(+) T cells and TILs in patients with locally advanced or metastatic solid tumours
  Journal ArticleModerateKim GM, et al.2025-01-01T00:00:00.000000Z
• Efineptakin alfa (NT-I7) improves overall survival and induces tertiary lymphoid structures in murine lung tumors
  Journal ArticleLowDinh T, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions